Spirovant Sciences Competitors and Similar CompaniesClear all

Spirovant Sciences's competitors and similar companies include Vertex Pharmaceuticals, Amneal Pharmaceuticals, Asklepios BioPharmaceutical and Cell Therapies.

	Spirovant Sciences Spirovant Sciences is a company focused on the development of gene therapies for treating and curing cystic fibrosis and other lung diseases.	Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.	Amneal Pharmaceuticals Amneal Pharmaceuticals is a company engaged in the development, manufacturing, and distribution of generic and specialty pharmaceutical products.	Asklepios BioPharmaceutical Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein.	Cell Therapies Cell Therapies is a manufacturer of cell therapies, gene therapies, cellular immunotherapies, and regenerative medicine products.
Founding Date	Founding Date 2016	Founding Date 1989	Founding Date 2002	Founding Date 2001	Founding Date 2003
Type	Type Private	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare genetics pharma therapy	Tags Healthcare biotech drug development pharma	Tags Healthcare distribution drug development oncology pharma therapy	Tags Healthcare biotech genetics pharma therapy	Tags Healthcare biotech genetics pharma therapy
Locations	Locations Philadelphia, US HQ	Locations Boston, US HQ St Leonards, AU Wien, AT Bruxelles, BE São Paulo, BR Toronto, CA Praha, CZ see more	Locations Bridgewater Township, US HQ Gröbenzell, DE Ahmedabad, IN Ahmedabad, IN Ahmedabad, IN Dahej, IN Mahabubnagar, IN see more	Locations Chapel Hill, US HQ Roslin, GB	Locations Melbourne, AU HQ
Employees	Employees 234% decrease	Employees 5,40013% increase	Employees 8,1005% increase	Employees 5172% increase	Employees 733% decrease
Valuation ($)	Valuation ($) N/A	Valuation ($) 121.4 b	Valuation ($) 2.6 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $12b (FY, 2025)	Revenue (est.) $3b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $1.7b (FY, 2025)	Cost of goods $1.9b (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $10.4b (FY, 2025)	Gross profit $1.1b (FY, 2025)	Gross profit N/A	Gross profit N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 2.4m	Total funding raised N/A	Total funding raised $ 235m	Total funding raised N/A